Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(3‑Phenyl‑2‑sulfanylpropanoyl)phenylalanylalanine is a synthetic dipeptide small molecule, classified as an experimental compound. It consists of a phenyl-substituted sulfhydryl propanoyl group linked to the dipeptide phenylalanylalanine. The compound has not been approved for any medical use and there are no known clinical trials or indications associated with it. Its mechanism of action, pharmacological activity, and therapeutic potential have not been described in the literature or major drug databases[1][3][4]. It is primarily referenced in chemical and structural biology resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(3-Phenyl-2-sulfanylpropanoyl)phenylalanylalanine.